BioSpace News Archive

MAIA Biotechnology, Inc. today announced dose selection for THIO-101, a Phase 2 clinical trial evaluating its lead asset, THIO, in sequential combination with Regeneron’s anti-PD-1 cemiplimab (Libtayo ® ).

Alora Pharmaceuticals, LLC , the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii ® (methylphenidate hydrochloride extended-release tablets).

XOMA Corporation announced it entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital with certain funds managed by the credit platform of Blue Owl Capital Inc..

Zimmer Biomet Holdings, Inc. today announced that members of the Zimmer Biomet management team will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 , at 8:15 a.m. PT ( 11:15 a.m. ET ).

Syros Pharmaceuticals announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024.

Medigene AG will be attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco to be held from January 8-11, 2024.

Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal (GI) disorders through targeted delivery of JAK inhibitors for its NaviCap™ targeted oral delivery platform under development.

As we bid farewell to 2023, it is with great enthusiasm that we share with you the accomplishments and progress that the Thryv team has achieved over the past year.

Aqtual announced today that Gregg C. Fergus has joined as a member of its board of directors.